TRENTON, N.J. Bristol-Myers Squibb Co. trounced Wall Street's first-quarter profit expectations as soaring sales of key new medicines offset higher expenses and a big hit from generic competition. Those factors left the drugmaker with a nearly flat profit despite revenue jumping 9 per cent, a sales trend that bodes well for the future, and Bris
Public Health is a state subject. Under the National Health Mission, support is provided to State for strengthening their healthcare system including support for provision of free generic drugs to those who access public health facilities including in rural areas, based on the requirement posed by the States/UTs in their Programme Implementation Pl
Since 2008, Latin America has been one of the fastest growing pharmaceutical markets in the world, driven by generic drugs manufactured by local companies and biosimilars manufactured both by multinational and local pharmaceutical companies. These specialists have designed customized supply chain solutions for all phases of research and drug...
ANI Pharmaceuticals, Inc. today announced the appointment of Stephen P. Carey to the position of Vice President and Chief Financial Officer, effective May 6, 2016. Steve has held various financial and accounting positions with Schering Plough Corporation and most recently, Par Pharmaceutical Companies, Inc., where he was the Senior Vice President
BriskInsights.com has announced the addition of "Global Biosimilars Market Size, Share, Trends, Growth, Analysis And Forecast To 2022" Market Research Report to their Database. According to a recently published report, the Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022. The segmentation of global biosimilars market is
Generika Drugstore, to recall, is the third-largest player in the country's pharmaceutical industry, one-half of which is now owned by Ayala Corp. The other players are Mercury Drug, the country's top pharmaceutical firm, and Generics Pharmacy, the country's largest generic-drugs retailer. The Philippines, as noted in this space earlier, has one of
The Delhi High Court has stated that the approval given by the Government of India to Biocon and Mylan to manufacture a breast cancer drug in India patented by Roche was not in line with either international guidelines on similar biologics or with the Drugs and Cosmetics Act. Roche holds the patent for the innovator molecule trastuzumab in India an
In the last year, Formycon has made great strides with the initiation of the clinical Phase III study involving the biosimilar candidate FYB201 in particular. At the same time, Formycon was able to license out a further biosimilar project- FYB203- from its pipeline to Santo Holding GmbH in 2015. Consequently, Formycon's development pipeline compris
Transparency Market Research Report Added "Biosimilar and Follow-On Biologics Market" to its database.Albany, NY 04/27/2016 The high demand for low-cost biologics is helping change the dynamics of the global biosimilar and follow-on biologics market. This, combined with several milestone commercial and regulatory developments will have a cons
Remicade biosimilar "NK" A slow start does not pull back NK in starting PhIII for Herceptin BS in Japan Active companies in Biosimilar Space: Local Japanese Generic Giants- Opening door for Biosimilars in Japan? We see that Abenomics measures and government involvement in biosimilar use would lead to the same type of progress for complex mAb Bio
NDA Partners Chairman Carl Peck, MD, announced today that Jon Clark has joined the company as an Expert Consultant. Mr. Clark also served as a CMC Electronic Submissions Expert, Office of Information Management and a Review Chemist in Office of Generic Drugs. "We are very pleased to welcome him to NDA Partners."
Pat McCrory announced Tuesday 275 pharma-manufacturing jobs are coming to Durham. We welcome the decision by Aurobindo Pharma to undertake this significant expansion in the Research Triangle, said McCrory. Aurobindo Pharma, a New Jersey- based maker of generic pharmaceuticals, said it will invest more than $31.7 million in a Durham headquarters for
April 26 DURHAM Generic drugmaker Aurobindo Pharma USA announced Tuesday that it will be investing $37.1 million for a new research and development headquarters in Durham, which is expected to create 275 jobs. The company already employs 14 scientists in Raleigh and estimates that the new Durham operation will create a $17.1 million payroll wit
April 26 DURHAM Generic drugmaker Aurobindo Pharma USA plans to establish a new research and development facility in Durham and create 275 jobs by the end of 2020.. Aurobindo is currently in negotiations to buy and renovate an existing manufacturing facility in Durham, said Ted Connor, vice president of economic development and community sustai
Glenmark Pharmaceuticals has been granted tentative approval by the United States Food& Drug Administration for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0. 01 mg, Ethinyl Estradiol Tablets USP, 0.01 mg and Ferrous Fumarate Tablets, 75 mg, the generic version of Lo Loestrin Fe Tablets of Allergan Pharms Intl. Glenmark will marke
After a heated few weeks at Taj Pharmaceuticals Ltd. and raised questions related to Counterfeit Carmustine 100 mg Injections; all the allegations have been dropped by Emcure Pharmaceuticals for their brand misuses. The Hon'ble High Court, Justice Gautam Patel during hearing from both companies, guided the difference between generic and brands on..
Shares of Horizon Pharma plc declined -1.04% to finish at $16.22 in last run as Horizon Pharma reported that settlement of Pennstated 2% patent litigation with Amneal Pharmaceuticals. Under the settlement and license contract, Horizon has granted Amneal the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the U.S
Swiss drug-maker Novartis is working with investment banks to line up potential buyers for its 13.5 billion francs' worth stake in Roche, according to Swiss newspaper Sonntagszeitung. According to the paper, Novartis wants to take bids from select investors to make sure that the buyers would be acceptable to Roche. Novartis' first-quarter core net
Lex Machina, a LexisNexis company and creator of Legal Analytics , today announced the release of its second Hatch-Waxman/ANDA Report, which surveys the landscape of patent litigation related to Abbreviated New Drug Applications submitted to the FDA under the Hatch-Waxman Act. The two U.S. districts that have received an overwhelming majority o
Johnson& Johnson has emerged as a safe bet for investors looking to bet big on a stock market grappling with uncertainty. Johnson& Johnson pharmaceutical business continues to deliver impressive levels of growth fueling optimism of what the future holds. Johnson& Johnson has already received a $180- day notice on the launch of a biosimilar for its
Dublin- Research and Markets has announced the addition of the "US Biosimilars Market Opportunity& Clinical Pipeline Analysis" report to their offering. Biologics have dominated the US market for several decades due to absence of worthy competitor in different disease segment. In coming years, this situation is expected to change as biosimilars are
Research and Markets has announced the addition of the "US Biosimilars Market Opportunity& Clinical Pipeline Analysis" report to their offering. US Biosimilars Market Introduction US Biosimilars Regulatory Scenario Unique Features of US Biosimilars Market Impact of Biosimilars in US Market Impact of Reimbursement Policies on US Biosimilars Market..
By a News Reporter-Staff News Editor at Pharma Business Week Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, is pleased to announce the appointment of Mr. Harold. Mr. Deas, who will retain his role as Chief Operating Officer, has been instrumental in helping Acella build a successful portfolio of generic and specialty, niche phar
This determination will allow FDA to approve abbreviated new drug applications for chlorthalidone USP tablets, 15 mg, if all other legal and regulatory requirements are met. The 1984 amendments include what is now section 505 of the Federal Food, Drug, and Cosmetic Act, which requires FDA to publish a list of all approved drugs. FDA publishes this
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting on the Animal Generic Drug User Fee Act. LOCATION: FDA, 7519 Standish Place, Third Floor, Room A, Rockville, Md.. CONTACT: Cassie Ravo, 240-402-6866, Cassie.Ravo@fda.hhs.gov.